Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy
Udenafil is a selective phosphodiesterase type 5 inhibitor made available in recent years for the treatment of erectile dysfunction. Herein, we evaluated independent predictors of potency recovery in radical prostatectomy (RP) patients who underwent penile rehabilitation with udenafil 50 mg. One hun...
Gespeichert in:
| Veröffentlicht in: | International journal of impotence research 2016-01, Vol.28 (1), p.25-30 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 30 |
|---|---|
| container_issue | 1 |
| container_start_page | 25 |
| container_title | International journal of impotence research |
| container_volume | 28 |
| creator | Kim, T-H Ha, Y-S Choi, S H Yoo, E S Kim, B W Yun, S-J Kim, W-J Kwon, Y S Kwon, T G |
| description | Udenafil is a selective phosphodiesterase type 5 inhibitor made available in recent years for the treatment of erectile dysfunction. Herein, we evaluated independent predictors of potency recovery in radical prostatectomy (RP) patients who underwent penile rehabilitation with udenafil 50 mg. One hundred and forty-three men who underwent RP were enrolled in a penile rehabilitation program using udenafil 50 mg every other day. The rate of regained potency in the study group was significantly higher compared with the recovery rate seen in patients who were not part of the penile rehabilitation program (41.3% vs 13.0%;
P |
| doi_str_mv | 10.1038/ijir.2015.28 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760906643</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A650065793</galeid><sourcerecordid>A650065793</sourcerecordid><originalsourceid>FETCH-LOGICAL-c584t-ad2fb38097f40347169c7a1de21509ed648e7e1b11cfb992cb06230cb1aea2ec3</originalsourceid><addsrcrecordid>eNqFkk-LFDEQxYMo7rh68ywNgniwx_zvznFYXBUWvOg5pNPVMxnSnTFJs-xtr35NP4lpZtVRFiWHHPKr9ypVD6HnBK8JZu1bt3dxTTERa9o-QCvCG1kL3qqHaIWVELVSDJ-hJyntMcYKE_kYnVEpCFZSrtD-0tgcYqoOEXpns5u2VZizDSOkKgzVASbnoYqwM53zLpvswlRdu7yr5h4mMzhfCfz99tu4rYbgfbheFKIpWsYX0ZBKCRSL8eYpejQYn-DZ3X2Ovly--3zxob769P7jxeaqtqLluTY9HTrWYtUMHDPeEKlsY0gPlAisoJe8hQZIR4gdOqWo7bCkDNuOGDAULDtHr4-6xf3rDCnr0SUL3psJwpw0aWSZg5ScFfTlX-g-zHEq3WkquWCMYUb-RZFGcEFxUftNbY0H7aYh5GjsYq03nOOWUiZVodb3UOX0MDobJigDhT8LXp0U7MD4vEvBz8sekt5IUcxFo9j_wFPFN0fQlu2kCIM-RDeaeKMJ1kuk9BIpvURK07bgL-5-P3cj9L_gnxkqQH0EUnmathBPxnOf4A9YUtRn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1754520066</pqid></control><display><type>article</type><title>Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Kim, T-H ; Ha, Y-S ; Choi, S H ; Yoo, E S ; Kim, B W ; Yun, S-J ; Kim, W-J ; Kwon, Y S ; Kwon, T G</creator><creatorcontrib>Kim, T-H ; Ha, Y-S ; Choi, S H ; Yoo, E S ; Kim, B W ; Yun, S-J ; Kim, W-J ; Kwon, Y S ; Kwon, T G</creatorcontrib><description>Udenafil is a selective phosphodiesterase type 5 inhibitor made available in recent years for the treatment of erectile dysfunction. Herein, we evaluated independent predictors of potency recovery in radical prostatectomy (RP) patients who underwent penile rehabilitation with udenafil 50 mg. One hundred and forty-three men who underwent RP were enrolled in a penile rehabilitation program using udenafil 50 mg every other day. The rate of regained potency in the study group was significantly higher compared with the recovery rate seen in patients who were not part of the penile rehabilitation program (41.3% vs 13.0%;
P
<0.001). On the multivariate Cox analyses, preoperative International Index of Erectile Function-5 scores (hazard ratio (HR), 1.049;
P
=0.040), alcohol consumption (HR, 2.043;
P
=0.020) and Gleason biopsy score (HR, 0.368;
P
=0.024) were independent preoperative predictors for potency recovery. Among post-RP variables, the use of robotic procedures (HR, 2.287;
P
=0.030) and pathologic stage (HR, 0.506;
P
=0.038) were significantly associated with potency recovery. This study identified predictive factors for the recovery of potency in patients undergoing penile rehabilitation with udenafil following RP. Our results could provide physicians with useful information for counseling RP patients and selecting optimal candidates for penile rehabilitation.</description><identifier>ISSN: 0955-9930</identifier><identifier>EISSN: 1476-5489</identifier><identifier>DOI: 10.1038/ijir.2015.28</identifier><identifier>PMID: 26510966</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>59/57 ; 692/499 ; 692/699/2768/1575 ; Aged ; Biopsy ; Care and treatment ; Complications and side effects ; Drug therapy ; Enzyme inhibitors ; Erectile dysfunction ; Erectile Dysfunction - drug therapy ; Erectile Dysfunction - etiology ; Erectile Dysfunction - physiopathology ; Erectile Dysfunction - rehabilitation ; Health aspects ; Humans ; Impotence ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; original-article ; Patients ; Penis ; Pharmaceutical industry ; Phosphodiesterase 5 Inhibitors - administration & dosage ; Postoperative Complications - drug therapy ; Postoperative Complications - physiopathology ; Postoperative Complications - rehabilitation ; Prognosis ; Prostate cancer ; Prostatectomy ; Prostatectomy - adverse effects ; Prostatectomy - methods ; Prostatic Neoplasms - surgery ; Pyrimidines - administration & dosage ; Recovery of Function - drug effects ; Recovery of Function - physiology ; Rehabilitation ; Reproductive Medicine ; Republic of Korea ; Review boards ; Risk Factors ; rology ; Sexual disorders ; Sulfonamides - administration & dosage ; Surgery ; Treatment Outcome ; Urological surgery ; Urology</subject><ispartof>International journal of impotence research, 2016-01, Vol.28 (1), p.25-30</ispartof><rights>Macmillan Publishers Limited 2016</rights><rights>COPYRIGHT 2016 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jan 2016</rights><rights>Macmillan Publishers Limited 2016.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c584t-ad2fb38097f40347169c7a1de21509ed648e7e1b11cfb992cb06230cb1aea2ec3</citedby><cites>FETCH-LOGICAL-c584t-ad2fb38097f40347169c7a1de21509ed648e7e1b11cfb992cb06230cb1aea2ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/ijir.2015.28$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/ijir.2015.28$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26510966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, T-H</creatorcontrib><creatorcontrib>Ha, Y-S</creatorcontrib><creatorcontrib>Choi, S H</creatorcontrib><creatorcontrib>Yoo, E S</creatorcontrib><creatorcontrib>Kim, B W</creatorcontrib><creatorcontrib>Yun, S-J</creatorcontrib><creatorcontrib>Kim, W-J</creatorcontrib><creatorcontrib>Kwon, Y S</creatorcontrib><creatorcontrib>Kwon, T G</creatorcontrib><title>Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy</title><title>International journal of impotence research</title><addtitle>Int J Impot Res</addtitle><addtitle>Int J Impot Res</addtitle><description>Udenafil is a selective phosphodiesterase type 5 inhibitor made available in recent years for the treatment of erectile dysfunction. Herein, we evaluated independent predictors of potency recovery in radical prostatectomy (RP) patients who underwent penile rehabilitation with udenafil 50 mg. One hundred and forty-three men who underwent RP were enrolled in a penile rehabilitation program using udenafil 50 mg every other day. The rate of regained potency in the study group was significantly higher compared with the recovery rate seen in patients who were not part of the penile rehabilitation program (41.3% vs 13.0%;
P
<0.001). On the multivariate Cox analyses, preoperative International Index of Erectile Function-5 scores (hazard ratio (HR), 1.049;
P
=0.040), alcohol consumption (HR, 2.043;
P
=0.020) and Gleason biopsy score (HR, 0.368;
P
=0.024) were independent preoperative predictors for potency recovery. Among post-RP variables, the use of robotic procedures (HR, 2.287;
P
=0.030) and pathologic stage (HR, 0.506;
P
=0.038) were significantly associated with potency recovery. This study identified predictive factors for the recovery of potency in patients undergoing penile rehabilitation with udenafil following RP. Our results could provide physicians with useful information for counseling RP patients and selecting optimal candidates for penile rehabilitation.</description><subject>59/57</subject><subject>692/499</subject><subject>692/699/2768/1575</subject><subject>Aged</subject><subject>Biopsy</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Drug therapy</subject><subject>Enzyme inhibitors</subject><subject>Erectile dysfunction</subject><subject>Erectile Dysfunction - drug therapy</subject><subject>Erectile Dysfunction - etiology</subject><subject>Erectile Dysfunction - physiopathology</subject><subject>Erectile Dysfunction - rehabilitation</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Impotence</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>original-article</subject><subject>Patients</subject><subject>Penis</subject><subject>Pharmaceutical industry</subject><subject>Phosphodiesterase 5 Inhibitors - administration & dosage</subject><subject>Postoperative Complications - drug therapy</subject><subject>Postoperative Complications - physiopathology</subject><subject>Postoperative Complications - rehabilitation</subject><subject>Prognosis</subject><subject>Prostate cancer</subject><subject>Prostatectomy</subject><subject>Prostatectomy - adverse effects</subject><subject>Prostatectomy - methods</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Pyrimidines - administration & dosage</subject><subject>Recovery of Function - drug effects</subject><subject>Recovery of Function - physiology</subject><subject>Rehabilitation</subject><subject>Reproductive Medicine</subject><subject>Republic of Korea</subject><subject>Review boards</subject><subject>Risk Factors</subject><subject>rology</subject><subject>Sexual disorders</subject><subject>Sulfonamides - administration & dosage</subject><subject>Surgery</subject><subject>Treatment Outcome</subject><subject>Urological surgery</subject><subject>Urology</subject><issn>0955-9930</issn><issn>1476-5489</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkk-LFDEQxYMo7rh68ywNgniwx_zvznFYXBUWvOg5pNPVMxnSnTFJs-xtr35NP4lpZtVRFiWHHPKr9ypVD6HnBK8JZu1bt3dxTTERa9o-QCvCG1kL3qqHaIWVELVSDJ-hJyntMcYKE_kYnVEpCFZSrtD-0tgcYqoOEXpns5u2VZizDSOkKgzVASbnoYqwM53zLpvswlRdu7yr5h4mMzhfCfz99tu4rYbgfbheFKIpWsYX0ZBKCRSL8eYpejQYn-DZ3X2Ovly--3zxob769P7jxeaqtqLluTY9HTrWYtUMHDPeEKlsY0gPlAisoJe8hQZIR4gdOqWo7bCkDNuOGDAULDtHr4-6xf3rDCnr0SUL3psJwpw0aWSZg5ScFfTlX-g-zHEq3WkquWCMYUb-RZFGcEFxUftNbY0H7aYh5GjsYq03nOOWUiZVodb3UOX0MDobJigDhT8LXp0U7MD4vEvBz8sekt5IUcxFo9j_wFPFN0fQlu2kCIM-RDeaeKMJ1kuk9BIpvURK07bgL-5-P3cj9L_gnxkqQH0EUnmathBPxnOf4A9YUtRn</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Kim, T-H</creator><creator>Ha, Y-S</creator><creator>Choi, S H</creator><creator>Yoo, E S</creator><creator>Kim, B W</creator><creator>Yun, S-J</creator><creator>Kim, W-J</creator><creator>Kwon, Y S</creator><creator>Kwon, T G</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160101</creationdate><title>Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy</title><author>Kim, T-H ; Ha, Y-S ; Choi, S H ; Yoo, E S ; Kim, B W ; Yun, S-J ; Kim, W-J ; Kwon, Y S ; Kwon, T G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c584t-ad2fb38097f40347169c7a1de21509ed648e7e1b11cfb992cb06230cb1aea2ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>59/57</topic><topic>692/499</topic><topic>692/699/2768/1575</topic><topic>Aged</topic><topic>Biopsy</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Drug therapy</topic><topic>Enzyme inhibitors</topic><topic>Erectile dysfunction</topic><topic>Erectile Dysfunction - drug therapy</topic><topic>Erectile Dysfunction - etiology</topic><topic>Erectile Dysfunction - physiopathology</topic><topic>Erectile Dysfunction - rehabilitation</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Impotence</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>original-article</topic><topic>Patients</topic><topic>Penis</topic><topic>Pharmaceutical industry</topic><topic>Phosphodiesterase 5 Inhibitors - administration & dosage</topic><topic>Postoperative Complications - drug therapy</topic><topic>Postoperative Complications - physiopathology</topic><topic>Postoperative Complications - rehabilitation</topic><topic>Prognosis</topic><topic>Prostate cancer</topic><topic>Prostatectomy</topic><topic>Prostatectomy - adverse effects</topic><topic>Prostatectomy - methods</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Pyrimidines - administration & dosage</topic><topic>Recovery of Function - drug effects</topic><topic>Recovery of Function - physiology</topic><topic>Rehabilitation</topic><topic>Reproductive Medicine</topic><topic>Republic of Korea</topic><topic>Review boards</topic><topic>Risk Factors</topic><topic>rology</topic><topic>Sexual disorders</topic><topic>Sulfonamides - administration & dosage</topic><topic>Surgery</topic><topic>Treatment Outcome</topic><topic>Urological surgery</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, T-H</creatorcontrib><creatorcontrib>Ha, Y-S</creatorcontrib><creatorcontrib>Choi, S H</creatorcontrib><creatorcontrib>Yoo, E S</creatorcontrib><creatorcontrib>Kim, B W</creatorcontrib><creatorcontrib>Yun, S-J</creatorcontrib><creatorcontrib>Kim, W-J</creatorcontrib><creatorcontrib>Kwon, Y S</creatorcontrib><creatorcontrib>Kwon, T G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of impotence research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, T-H</au><au>Ha, Y-S</au><au>Choi, S H</au><au>Yoo, E S</au><au>Kim, B W</au><au>Yun, S-J</au><au>Kim, W-J</au><au>Kwon, Y S</au><au>Kwon, T G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy</atitle><jtitle>International journal of impotence research</jtitle><stitle>Int J Impot Res</stitle><addtitle>Int J Impot Res</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>28</volume><issue>1</issue><spage>25</spage><epage>30</epage><pages>25-30</pages><issn>0955-9930</issn><eissn>1476-5489</eissn><abstract>Udenafil is a selective phosphodiesterase type 5 inhibitor made available in recent years for the treatment of erectile dysfunction. Herein, we evaluated independent predictors of potency recovery in radical prostatectomy (RP) patients who underwent penile rehabilitation with udenafil 50 mg. One hundred and forty-three men who underwent RP were enrolled in a penile rehabilitation program using udenafil 50 mg every other day. The rate of regained potency in the study group was significantly higher compared with the recovery rate seen in patients who were not part of the penile rehabilitation program (41.3% vs 13.0%;
P
<0.001). On the multivariate Cox analyses, preoperative International Index of Erectile Function-5 scores (hazard ratio (HR), 1.049;
P
=0.040), alcohol consumption (HR, 2.043;
P
=0.020) and Gleason biopsy score (HR, 0.368;
P
=0.024) were independent preoperative predictors for potency recovery. Among post-RP variables, the use of robotic procedures (HR, 2.287;
P
=0.030) and pathologic stage (HR, 0.506;
P
=0.038) were significantly associated with potency recovery. This study identified predictive factors for the recovery of potency in patients undergoing penile rehabilitation with udenafil following RP. Our results could provide physicians with useful information for counseling RP patients and selecting optimal candidates for penile rehabilitation.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>26510966</pmid><doi>10.1038/ijir.2015.28</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0955-9930 |
| ispartof | International journal of impotence research, 2016-01, Vol.28 (1), p.25-30 |
| issn | 0955-9930 1476-5489 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1760906643 |
| source | MEDLINE; SpringerNature Journals |
| subjects | 59/57 692/499 692/699/2768/1575 Aged Biopsy Care and treatment Complications and side effects Drug therapy Enzyme inhibitors Erectile dysfunction Erectile Dysfunction - drug therapy Erectile Dysfunction - etiology Erectile Dysfunction - physiopathology Erectile Dysfunction - rehabilitation Health aspects Humans Impotence Male Medicine Medicine & Public Health Middle Aged original-article Patients Penis Pharmaceutical industry Phosphodiesterase 5 Inhibitors - administration & dosage Postoperative Complications - drug therapy Postoperative Complications - physiopathology Postoperative Complications - rehabilitation Prognosis Prostate cancer Prostatectomy Prostatectomy - adverse effects Prostatectomy - methods Prostatic Neoplasms - surgery Pyrimidines - administration & dosage Recovery of Function - drug effects Recovery of Function - physiology Rehabilitation Reproductive Medicine Republic of Korea Review boards Risk Factors rology Sexual disorders Sulfonamides - administration & dosage Surgery Treatment Outcome Urological surgery Urology |
| title | Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A55%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20predicting%20outcomes%20of%20penile%20rehabilitation%20with%20udenafil%2050%E2%80%89mg%20following%20radical%20prostatectomy&rft.jtitle=International%20journal%20of%20impotence%20research&rft.au=Kim,%20T-H&rft.date=2016-01-01&rft.volume=28&rft.issue=1&rft.spage=25&rft.epage=30&rft.pages=25-30&rft.issn=0955-9930&rft.eissn=1476-5489&rft_id=info:doi/10.1038/ijir.2015.28&rft_dat=%3Cgale_proqu%3EA650065793%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1754520066&rft_id=info:pmid/26510966&rft_galeid=A650065793&rfr_iscdi=true |